Risk factors and comorbidities in diabetic neuropathy: The 2015 update

Review of Diabetic Studies

Volumn 12, Issue 1, 2015, Pages

  Papanas, Nikolaos ^a   Ziegler, Dan ^b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Diabetes; Diabetic neuropathy; Hyperglycemia; Hypertension; Prediabetes; Prevalence; Risk factors

Indexed keywords

ALCOHOL; APOLIPOPROTEIN E; GLUCOSE; GLUTATHIONE; GROWTH FACTOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; METHYLGLYOXAL; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL;

ARTERY CALCIFICATION; ARTICLE; AUTONOMIC NEUROPATHY; CARDIAC AUTONOMIC NEUROPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COGNITIVE DEFECT; DEPRESSION; DIABETIC NEUROPATHY; DISTAL SYMMETRIC SENSORIMOTOR POLYNEUROPATHY; DYSLIPIDEMIA; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL ACTIVITY; RETINOPATHY; RISK FACTOR; SENSORIMOTOR NEUROPATHY; SLEEP DISORDERED BREATHING;

EID: 84947607120     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: None     Document Type: Article

References (159)

1. Ziegler D, Papanas N, Vinik AI, Shaw JE. Epidemiology of polyneuropathy in diabetes and prediabetes. Handb Clin Neurol 2014. 126:3-22.
2. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010. 33(10):2285-2293.
3. Papanas N, Vinik AI, Ziegler D. Neuropathy in prediabetes: does the clock start ticking early? Nat Rev Endocrinol 2011. 7(11):682-690.
4. Boulton AJ. The diabetic foot: grand overview, epidemiology and pathogenesis. Diabetes Metab Res Rev 2008. 24(Suppl 1):S3-S6.
5. Papanas N, Maltezos E. The diabetic foot: established and emerging treatments. Acta Clin Belg 2007. 62(4):230-238.
6. Papanas N, Ziegler D. New vistas in the diagnosis of diabetic polyneuropathy. Endocrine 2014. 47(3):690-698.
7. Papanas N, Ziegler D. Corneal confocal microscopy: a new technique for early detection of diabetic neuropathy. Curr Diab Rep 2013. 13(4):488-499.
8. Papanas N, Boulton AJ, Malik RA, Manes C, Schnell O, Spallone V, Tentolouris N, Tesfaye S, Valensi P, Ziegler D, et al. A simple new non-invasive sweat indicator test for the diagnosis of diabetic neuropathy. Diabet Med 2013. 30(5):525-534.
9. Körei AE, Istenes I, Papanas N, Kempler P. Small-fiber neuropathy: a diabetic microvascular complication of special clinical, diagnostic, and prognostic importance. Angiology 2015. In press.
10. Young MJ, Breddy JL, Veves A, Boulton AJ. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care 1994. 17(6):557-560.
11. Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 1996. 39(11):1377-1384.
12. Adler AI, Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Smith DG. Risk factors for diabetic peripheral sensory neuropathy. Results of the Seattle Prospective Diabetic Foot Study. Diabetes Care 1997. 20(7):1162-1167.
13. Forrest KY, Maser RE, Pambianco G, Becker DJ, Orchard TJ. Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes 1997. 46(4):665-670.
14. Shaw JE, Hodge AM, de Courten M, Dowse GK, Gareeboo H, Tuomilehto J, Alberti KG, Zimmet PZ. Diabetic neuropathy in Mauritius: prevalence and risk factors. Diabetes Res Clin Pract 1998. 42(2):131-139.
15. Sands ML, Shetterly SM, Franklin GM, Hamman RF. Incidence of distal symmetric (sensory) neuropathy in NIDDM. The San Luis Valley Diabetes Study. Diabetes Care 1997. 20(3):322-329.
16. Albers JW, Herman WH, Pop-Busui R, Feldman EL, Martin CL, Cleary PA, Waberski BH, Lachin JM, Diabetes Control and Complications Trial /Epidemiology of Diabetes Interventions and Complications Research Group. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 2010. 33(5):1090-1096.
17. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4000 patients observed between 1947 and 1973. Diabetes Care 1978. 1(1):168-188.
18. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4000 patients observed between 1947 and 1973. Diabetes Care 1978. 1(2):252-263.
19. Martin CL, Albers JW, Pop-Busui R, DCCT/EDIC Research Group. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014. 37(1):31-38.
20. Ziegler D, Behler M, Schroers-Teuber M, Roden M. Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes. BMJ Open 2015. 5:e006559.
21. Papanas N, Ziegler D. Polyneuropathy in impaired glucose tolerance: is postprandial hyperglycemia the main culprit? A mini-review. Gerontology 2013. 59(3):193-198.
22. Delcourt C, Vauzelle-Kervroedan F, Cathelineau G, Papoz L. Low prevalence of long-term complications in non-insulin-dependent diabetes mellitus in France: a multicenter study. CODIAB-INSERM-ZENECA Pharma Study Group. J Diabetes Complications 1998. 12(2):88-95.
23. Migdalis I, Leslie D, Mavrogiannaki A, Papanas N, Valensi P, Vlassara H. Diabetes Mellitus 2014. Int J Endocrinol 2015. 2015:845759.
24. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995. 333(2):89-94.
25. Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, Witte DR, Fuller JH, EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005. 352(4):341-350.
26. Davis TM, Yeap BB, Davis WA, Bruce DG. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 2008. 51(4):562-566.
27. Herman WH, Aubert RE, Engelgau MM, Thompson TJ, Ali MA, Sous ES, Hegazy M, Badran A, Kenny SJ, Gunter EW, et al. Diabetes mellitus in Egypt: glycaemic control and microvascular and neuropathic complications. Diabet Med 1998. 15(12):1045-1051.
28. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, Wilson DM, O’Brien PC, Melton LJ 3rd, Service FJ. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993. 43(4):817-824.
29. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993. 329(14):977-986.
30. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998. 352(9131):837-853.
31. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008. 358(24):2560-2572.
32. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009. 360(2):129-139.
33. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010. 376(9739):419-430.
34. Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev 2012. 6:CD007543.
35. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, Kassai B, Erpeldinger S, Wright JM, Gueyffier F, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011. 343:d4169.
36. Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH. Glucose variability; does it matter? Endocr Rev 2010. 31(2):171-182.
37. Ma WY, Li HY, Pei D, Hsia TL, Lu KC, Tsai LY, Wei JN, Su CC. Variability in hemoglobin A1c predicts all-cause mortality in patients with type 2 diabetes. J Diabetes Complications 2012. 26(4):296-300.
38. Skriver MV, Sandbaek A, Kristensen JK, Stovring H. Relationship of HbA1c variability, absolute changes in HbA1c, and all-cause mortality in type 2 diabetes: a Danish population-based prospective observational study. BMJ Open Diabetes Res Care 2015. 3:e000060.
39. Bragd J, Adamson U, Bäcklund LB, Lins PE, Moberg E, Oskarsson P. Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade? Diabetes Metab 2008. 34(6 Pt 1):612-616.
40. Siegelaar SE, Kilpatrick ES, Rigby AS, Atkin SL, Hoekstra JB, Devries JH. Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia 2009. 52(10):2229-2232.
41. Jun JE, Jin SM, Baek J, Oh S, Hur KY, Lee MS, Lee MK, Kim JH. The association between glycemic variability and diabetic cardiovascular autonomic neuropathy in patients with type 2 diabetes. Cardiovasc Diabetol 2015. 14:70.
42. Xu F, Zhao LH, Su JB, Chen T, Wang XQ, Chen JF, Wu G, Jin Y, Wang XH. The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c. Diabetol Metab Syndr 2014. 6(1):139.
43. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A, KORA Study Group. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008. 31(3):464-469.
44. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A, KORA Study Group. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med 2009. 10(2):393-400.
45. Ziegler D, Rathmann W, Meisinger C, Dickhaus T, Mielck A, KORA Study Group. Prevalence and risk factors of neuropathic pain in survivors of myocardial infarction with pre-diabetes and diabetes. The KORA Myocardial Infarction Registry. Eur J Pain 2009. 13(6):582-587.
46. Bongaerts BW, Rathmann W, Kowall B, Herder C, Stöckl D, Meisinger C, Ziegler D. Post-challenge hyperglycemia is positively associated with diabetic polyneuropathy: the KORA F4 study. Diabetes Care 2012. 35(9):1891-1893.
47. Ziegler D, Voss A, Rathmann W, Strom A, Perz S, Roden M, Peters A, Meisinger C, KORA Study Group. Increased prevalence of cardiac autonomic dysfunction at different degrees of glucose intolerance in the general population: the KORA S4 survey. Diabetologia 2015. 58(5):1118-1128.
48. Dyck PJ, Clark VM, Overland CJ, Davies JL, Pach JM, Dyck PJ, Klein CJ, Rizza RA, Melton LJ 3rd, Carter RE, et al. Impaired glycemia and diabetic polyneuropathy: The OC IG Survey. Diabetes Care 2012. 35(3):584-591.
49. Kassardjian CD, Dyck PJ, Davies JL, Carter RE, Dyck PJ. Does prediabetes cause small fiber sensory polyneuropathy? Does it matter? J Neurol Sci 2015. 355(1-2):196-198.
50. Walters DP, Gatling W, Mullee MA, Hill RD. The prevalence of diabetic distal sensory neuropathy in an English community. Diabet Med 1992. 9(4):349-53.
51. Franklin GM, Shetterly SM, Cohen JA, Baxter J, Hamman RF. Risk factors for distal symmetric neuropathy in NIDDM. The San Luis Valley Diabetes Study. Diabetes Care 1994. 17(10):1172-1177.
52. Martina IS, van Koningsveld R, Schmitz PI, van der Meche FG, van Doorn PA. Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. European Inflammatory Neuropathy Cause and Treatment (INCAT) group. J Neurol Neurosurg Psychiatry 1998. 65(5):743-747.
53. Savage S, Estacio RO, Jeffers B, Schrier RW. Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes Care 1996. 19(11):1243-1248.
54. The UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998. 317(7160):703-713.
55. Keech AC, Rajamani JK, Best JD, Hankey G, Donoghoe MW, Li L. Predictors of peripheral neuropathy and effects of fenofibrate among 9,795 subjects with type 2 diabetes: the fenofibrate intervention and event lowering in diabetes (FIELD) study. Diabetologia 2011. 54(Suppl 1):A180.
56. Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D’Emden MC, Laakso M, Baker JR, Keech AC, FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009. 373(9677):1780-1788.
57. Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 2009. 58(7):1634-1640.
58. Cho YN, Lee KO, Jeong J, Park HJ, Kim SM, Shin HY, Hong JM, Ahn CW, Choi YC. The role of insulin resistance in diabetic neuropathy in Koreans with type 2 diabetes mellitus: a 6-year follow-up study. Yonsei Med J 2014. 55(3):700-708.
59. Clair C, Cohen MJ, Eichler F, Selby KJ, Rigotti NA. The effect of cigarette smoking on diabetic peripheral neuropathy: a systematic review and meta-analysis. J Gen Intern Med 2015. 30(8):1193-1203.
60. Ylitalo KR, Sowers M, Heeringa S. Peripheral vascular disease and peripheral neuropathy in individuals with cardiometabolic clustering and obesity: National Health and Nutrition Examination Survey 2001-2004. Diabetes Care 2011. 34(7):1642-1647.
61. Herman RM, Brower JB, Stoddard DG, Casano AR, Targovnik JH, Herman JH, Tearse P. Prevalence of somatic small fiber neuropathy in obesity. Int J Obes (Lond) 2007. 31(2):226-235.
62. Smith AG, Rose K, Singleton JR. Idiopathic neuropathy patients are at high risk for metabolic syndrome. J Neurol Sci 2008. 273(1-2):25-28.
63. Pittenger GL, Mehrabyan A, Simmons K, Amandarice, Dublin C, Barlow P, Vinik AI. Small fiber neuropathy is associated with the metabolic syndrome. Metab Syndr Relat Disord 2005. 3(2):113-121.
64. Lee KO, Nam JS, Ahn CW, Hong JM, Kim SM, Sunwoo IN, Moon JS, Na SJ, Choi YC. Insulin resistance is independently associated with peripheral and autonomic neuropathy in Korean type 2 diabetic patients. Acta Diabetol 2012. 49(2):97-103.
65. Schmelzer JD, Zochodne DW, Low PA. Ischemic and reperfusion injury of rat peripheral nerve. Proc Natl Acad Sci USA 1989. 86(5):1639-1642.
66. Herbst U, Toborek M, Kaiser S, Mattson MP, Hennig B. 4-Hydroxynonenal induces dysfunction and apoptosis of cultured endothelial cells. J Cell Physiol 1999. 181(2):295-303.
67. Al-Rejaie SS, Aleisa AM, Abuohashish HM, Parmar MY, Ola MS, Al-Hosaini AA, Ahmed MM. Naringenin neutralises oxidative stress and nerve growth factor discrepancy in experimental diabetic neuropathy. Neurol Res 2015. In press.
68. Varkonyi T, Putz Z, Keresztes K, Martos T, Lengyel C, Stirban A, Jermendy G, Kempler P. Current options and perspectives in the treatment of diabetic neuropathy. Curr Pharm Des 2013. 19(27):4981-5007.
69. Mendez MM, Folgado J, Tormo C, Artero A, Ascaso M, Martinez-Hervas S, Chaves FJ, Ascaso JF, Real JT. Altered glutathione system is associated with the presence of distal symmetric peripheral polyneuropathy in type 2 diabetic subjects. J Diabetes Complications 2015. In press.
70. Kasznicki J, Kosmalski M, Sliwinska A, Mrowicka M, Stanczyk M, Majsterek I, Drzewoski J. Evaluation of oxidative stress markers in pathogenesis of diabetic neuropathy. Mol Biol Rep 2012. 39(9):8669-8678.
71. Bierhaus A, Fleming T, Stoyanov S, Leffler A, Babes A, Neacsu C, Sauer SK, Eberhardt M, Schnölzer M, Lasitschka F, et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med 2012. 18(6):926-933.
72. Migdalis IN, Triantafilou P, Petridou E, Varvarigos N, Totolos V, Rigopoulos A. Lipid peroxides in type 2 diabetic patients with neuropathy. Res Commun Mol Pathol Pharmacol 2005. 117-118:5-12.
73. Ziegler D, Strom A, Brüggemann J, Ziegler I, Ringel B, Püttgen S, Roden M, GDS Group. Overexpression of cutaneous mitochondrial superoxide dismutase in recent-onset type 2 diabetes. Diabetologia 2015. 58(7):1621-1625.
74. Ziegler D, Buchholz S, Sohr C, Nourooz-Zadeh J, Roden M. Oxidative stress predicts progression of peripheral and cardiac autonomic nerve dysfunction over 6 years in diabetic patients. Acta Diabetol 2015. 52(1):65-72.
75. Hoeldtke RD, Bryner KD, Hoeldtke ME, Christie I, Ganser G, Hobbs G, Riggs J. Sympathetic sudomotor disturbance in early type 1 diabetes mellitus is linked to lipid peroxidation. Metabolism 2006. 55(11):1524-1531.
76. Hoeldtke RD, Bryner KD, Corum LL, Hobbs GR, Van Dyke K. Lipid peroxidation in early type 1 diabetes mellitus is unassociated with oxidative damage to DNA. Metabolism 2009. 58(5):731-734.
77. Hoeldtke RD, Bryner KD, Van Dyke K. Oxidative stress and autonomic nerve function in early type 1 diabetes. Clin Auton Res 2011. 21(1):19-28.
78. Kajita K, Ishizuka T, Miura A, Kanoh Y, Ishizawa M, Kimura M, Yasuda K. Increased platelet aggregation in diabetic patients with microangiopathy despite good glycemic control. Platelets 2001. 12(6):343-351.
79. Demirtunc R, Duman D, Basar M, Bilgi M, Teomete M, Garip T. The relationship between glycemic control and platelet activity in type 2 diabetes mellitus. J Diabetes Complications 2009. 23(2):89-94.
80. Papanas N, Symeonidis G, Maltezos E, Mavridis G, Karavageli E, Vosnakidis T, Lakasas G. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets 2004. 15(8):475-478.
81. Xiao W, Huang Y, Dong J, Zhang X, Hu J. Relationship between platelet volume indices with macrovascular and peripheral neuropathy complications in type 2 diabetic patients. J Diabetes 2014. 6(4):298-303.
82. Papanas N, Mavridis G, Karavageli E, Symeonidis G, Maltezos E. Peripheral neuropathy is associated with increased mean platelet volume in type 2 diabetic patients. Platelets 2005. 16(8):498-499.
83. Shehab D, Al-Jarallah K, Mojiminiyi OA, Al Mohamedy H, Abdella NA. Does vitamin D deficiency play a role in peripheral neuropathy in type 2 diabetes? Diabet Med 2012. 29(1):43-49.
84. Shehab D, Al-Jarallah K, Abdella N, Mojiminiyi OA, Al Mohamedy H. Prospective evaluation of the effect of short-term oral vitamin D supplementation on peripheral neuropathy in type 2 diabetes mellitus. Med Princ Pract 2015. 24(3):250-256.
85. Jung CH, Jung SH, Kim KJ, Kim BY, Kim CH, Kang SK, Mok JO. The relationship between vitamin D status and cardiac autonomic neuropathy in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 2015. 12(5):342-351.
86. Hitman GA, Vitamin D, diabetic neuropathy and supplementation post-gestational diabetes. Diabet Med 2012. 29(1):1.
87. Putz Z, Martos T, Nemeth N, Körei AE, Vagi OE, Kempler MS, Kempler P. Is there an association between diabetic neuropathy and low vitamin D levels? Curr Diab Rep 2014. 14(10):537.
88. Gouveri E, Papanas N, Hatzitolios AI, Maltezos E. Hypovitaminosis D and peripheral arterial disease: emerging link beyond cardiovascular risk factors. Eur J Intern Med 2012. 23(8):674-681.
89. Herder C, Bongaerts BW, Ouwens DM, Rathmann W, Heier M, Carstensen-Kirberg M, Koenig W, Thorand B, Roden M, Meisinger C, et al. Low serum omentin levels in the elderly population with type 2 diabetes and polyneuropathy. Diabet Med 2015. In press.
90. Herder C, Bongaerts BW, Rathmann W, Heier M, Kowall B, Koenig W, Thorand B, Roden M, Meisinger C, Ziegler D. Differential association between biomarkers of subclinical inflammation and painful polyneuropathy. Results from the KORA F4 Study. Diabetes Care 2015. 38(1):91-96.
91. Herder C, Bongaerts BW, Rathmann W, Heier M, Kowall B, Koenig W, Thorand B, Roden M, Meisinger C, Ziegler D. Association of subclinical inflammation with polyneuropathy in the older population: KORA F4 Study. Diabetes Care 2013. 36(11):3663-3670.
92. Herder C, Lankisch M, Ziegler D, Rathmann W, Koenig W, Illig T, Döring A, Thorand B, Holle R, Giani G, et al. Subclinical inflammation and diabetic polyneuropathy: MONICA/KORA Survey F3 (Augsburg/Germany). Diabetes Care 2009. 32(4):680-682.
93. Papanas N, Katsiki N, Papatheodorou K, Demetriou M, Papazoglou D, Gioka T, Maltezos E. Peripheral neuropathy is associated with increased serum levels of uric acid in type 2 diabetes mellitus. Angiology 2011. 62(4):291-295.
94. Papanas N, Demetriou M, Katsiki N, Papatheodorou K, Papazoglou D, Gioka T, Kotsiou S, Maltezos E, Mikhailidis DP. Increased serum levels of uric acid are associated with sudomotor dysfunction in subjects with type 2 diabetes mellitus. Exp Diabetes Res 2011. 2011:346-051.
95. Leung L, Cahill CM. TNF-alpha and neuropathic pain - a review. J Neuroinflammation 2010. 7:27.
96. Yamakawa I, Kojima H, Terashima T, Katagi M, Oi J, Urabe H, Kawai H, Chan L, Yasuda H, Maegawa H, et al. Inactivation of TNF-α ameliorates diabetic neuropathy in mice. Am J Physiol Endocrinol Metab 2011. 301(5):E844-E852.
97. Vague P, Dufayet D, Coste T, Moriscot C, Jannot MF, Raccah D. Association of diabetic neuropathy with Na/K ATPase gene polymorphism. Diabetologia 1997. 40(5):506-511.
98. Raccah D, Gallice P, Pouget J, Vague P. Hypothesis: low Na/K-ATPase activity in the red cell membrane, a potential marker of the predisposition to diabetic neuropathy. Diabete Metab 1992. 18(3):236-241.
99. Heesom AE, Millward A, Demaine AG. Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5’ end of the aldose reductase gene. J Neurol Neurosurg Psychiatry 1998. 64(2):213-216.
100. Chung SS, Chung SK. Genetic analysis of aldose reductase in diabetic complications. Curr Med Chem 2003. 10(15):1375-1387.
101. Vague P, Coste TC, Jannot MF, Raccah D, Tsimaratos M. C-peptide, Na+,K(+)-ATPase, and diabetes. Exp Diabesity Res 2004. 5:37-50.
102. Nikitin AG, Chudakova DA, Strokov IA, Bursa TR, Chistiakov DA, Nosikov VV. Leu54Phe and Val762Ala polymorphisms in the poly(ADP-ribose)polymerase-1 gene are associated with diabetic polyneuropathy in Russian type 1 diabetic patients. Diabetes Res Clin Pract 2008. 79(3):446-452.
103. Chistiakov DA, Zotova EV, Savost’anov KV, Bursa TR, Galeev IV, Strokov IA. The 262T>C promoter polymorphism of the catalase gene is associated with diabetic neuropathy in type 1 diabetic Russian patients. Diabetes Metab 2006. 32(1):63-68.
104. Strokov IA, Bursa TR, Drepa OI, Zotova EV, Nosikov VV, Ametov AS. Predisposing genetic factors for diabetic polyneuropathy in patients with type 1 diabetes: a population-based case-control study. Acta Diabetol 2003. 40(Suppl 2):S375-S379.
105. Papanas N, Papatheodorou K, Papazoglou D, Kotsiou S, Christakidis D, Maltezos E. An insertion/deletion polymorphism in the alpha2B adrenoceptor gene is associated with peripheral neuropathy in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2007. 115(5):327-330.
106. Rudofsky G Jr, Reismann P, Witte S, Humpert PM, Isermann B, Chavakis T, Tafel J, Nosikov VV, Hamann A, Nawroth P, et al. Asp299Gly and Thr399Ile genotypes of the TLR4 gene are associated with a reduced prevalence of diabetic neuropathy in patients with type 2 diabetes. Diabetes Care 2004. 27(1):179-183.
107. Tsuzuki S, Murano T, Watanabe H, Itoh Y, Miyashita Y, Shirai K. The examination of apoE phenotypes in diabetic patients with peripheral neuropathy. Rinsho Byori 1998. 46(8):829-833.
108. Bedlack RS, Edelman D, Gibbs JW 3rd, Kelling D, Strittmatter W, Saunders AM, Morgenlander J. APOE genotype is a risk factor for neuropathy severity in diabetic patients. Neurology 2003. 60(6):1022-1024.
109. Zhou Z, Hoke A, Cornblath DR, Griffin JW, Polydefkis M. APOE epsilon4 is not a susceptibility gene in idiopathic or diabetic sensory neuropathy. Neurology 2005. 64(1):139-141.
110. Voron’ko OE, Yakunina NYu, Strokov IA, Lavrova IN, Nosikov VV. Association of polymorphic markers of the lipid metabolism genes with diabetic neuropathy in type 1 diabetes mellitus. Mol Biology 2005. 39(3):206-209.
111. Monastiriotis C, Papanas N, Veletza S, Maltezos E. APOE gene polymorphisms and diabetic peripheral neuropathy. Arch Med Sci 2012. 8(4):583-588.
112. Monastiriotis C, Papanas N, Trypsianis G, Karanikola K, Veletza S, Maltezos E. The ε4 allele of the APOE gene is associated with more severe peripheral neuropathy in type 2 diabetic patients. Angiology 2013. 64(6):451-455.
113. Davies B, Cramp F, Gauntlett-Gilbert J, Wynick D, McCabe CS. The role of physical activity and psychological coping strategies in the management of painful diabetic neuropathy - A systematic review of the literature. Physiotherapy 2015. In press.
114. Tiaka EK, Papanas N, Manolakis AC, Maltezos E. The role of nerve growth factor in the prophylaxis and treatment of diabetic foot ulcers. Int J Burns Trauma 2011. 1(1):68-76.
115. Migdalis IN, Kalogeropoulou K, Kalantzis L, Nounopoulos C, Bouloukos A, Samartzis M. Insulin-like growth factor-I and IGF-I receptors in diabetic patients with neuropathy. Diabet Med 1995. 12(9):823-827.
116. Guo H, Yang Y, Geng Z, Zhu L, Yuan S, Zhao Y, Gao Y, Fu H. The change of insulin-like growth factor-1 in diabetic patients with neuropathy. Chin Med J (Engl) 1999. 112(1):76-79.
117. Apfel SC, Schwartz S, Adornato BT, Freeman R, Biton V, Rendell M, Vinik A, Giuliani M, Stevens JC, Barbano R, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000. 284(17):2215-2221.
118. Vileikyte L, Leventhal H, Gonzalez JS, Peyrot M, Rubin RR, Ulbrecht JS, Garrow A, Waterman C, Cavanagh PR, Boulton AJ. Diabetic peripheral neuropathy and depressive symptoms: the association revisited. Diabetes Care 2005. 28(10):2378-2383.
119. Vileikyte L, Peyrot M, Gonzalez JS, Rubin RR, Garrow AP, Stickings D, Waterman C, Ulbrecht JS, Cavanagh PR, Boulton AJ. Predictors of depressive symptoms in persons with diabetic peripheral neuropathy: a longitudinal study. Diabetologia 2009. 52(7):1265-1273.
120. Vileikyte L, Gonzalez JS. Recognition and management of psychosocial issues in diabetic neuropathy. Handb Clin Neurol 2014. 126:195-209.
121. Vileikyte L, Peyrot M, Bundy C, Rubin RR, Leventhal H, Mora P, Shaw JE, Baker P, Boulton AJ. The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument. Diabetes Care 2003. 26(9):2549-2555.
122. Papanas N, Tsapas A, Papatheodorou K, Papazoglou D, Bekiari E, Sariganni M, Paletas K, Maltezos E. Glycaemic control is correlated with well-being index (WHO-5) in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2010. 118(6):364-367.
123. Patel SS, Udayabanu M. Effect of Urtica dioica on memory dysfunction and hypoalgesia in an experimental model of diabetic neuropathy. Neurosci Lett 2013. 552:114-119.
124. Rucker JL, Jernigan SD, McDowd JM, Kluding PM. Adults with diabetic peripheral neuropathy exhibit impairments in multitasking and other executive functions. J Neurol Phys Ther 2014. 38(2):104-110.
125. Roman de Mettelinge T, Delbaere K, Calders P, Gysel T, Van Den Noortgate N, Cambier D. The impact of peripheral neuropathy and cognitive decrements on gait in older adults with type 2 diabetes mellitus. Arch Phys Med Rehabil 2013. 94(6):1074-1079.
126. McCrimmon RJ, Ryan CM, Frier BM. Diabetes and cognitive dysfunction. Lancet 2012. 379(9833):2291-2299.
127. Ba-Tin L, Strike P, Tabet N. Diabetic peripheral microvascular complications: relationship to cognitive function. Cardiovasc Psychiatry Neurol 2011. 2011:723434.
128. Paul L, Ellis BM, Leese GP, McFadyen AK, McMurray B. The effect of a cognitive or motor task on gait parameters of diabetic patients, with and without neuropathy. Diabet Med 2009. 26(3):234-239.
129. Kim SH, Lee KA, Jin HY, Baek HS, Park TS. Relationship between the Korean version survey of the autonomic symptoms score and cardiac autonomic neuropathy parameters in patients with diabetic peripheral neuropathy. Diabetes Metab J 2014. 38(5):349-355.
130. Ratzmann KP, Raschke M, Gander I, Schimke E. Prevalence of peripheral and autonomic neuropathy in newly diagnosed type II (noninsulin-dependent) diabetes. J Diabet Complications 1991. 5(1):1-5.
131. Ziegler D, Gries FA, Mühlen H, Rathmann W, Spüler M, Lessmann F. Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes centers. The Diacan Multicenter Study Group. Diabete Metab 1993. 19(1 Pt 2):143-151.
132. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003. 26(5):1553-1579.
133. Gentile S, Bizzarro A, Marmo R, de Bellis A, Orlando C. Medial arterial calcification and diabetic neuropathy. Acta Diabetol Lat 1990. 27(3):243-253.
134. Vinik AI, Maser RE, Ziegler D. Neuropathy: the crystal ball for cardiovascular disease? Diabetes Care 2010. 33(7):1688-1690.
135. Brownrigg JR, de Lusignan S, McGovern A, Hughes C, Thompson MM, Ray KK, Hinchliffe RJ. Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus. Heart 2014. 100(23):1837-1843.
136. Kärvestedt L, Martensson E, Grill V, Elofsson S, von Wendt G, Hamsten A, Brismar K. Peripheral sensory neuropathy associates with micro- or macroangiopathy: results from a population-based study of type 2 diabetic patients in Sweden. Diabetes Care 2009. 32(2):317-322.
137. Papanas N, Symeonidis G, Mavridis G, Georgiadis GS, Papas TT, Lazarides MK, Maltezos E. Ankle-brachial index: a surrogate marker of microvascular complications in type 2 diabetes mellitus? Int Angiol 2007. 26(3):253-257.
138. Edmonds ME. Medial arterial calcification and diabetes mellitus. Z Kardiol 2000. 89(Suppl 2):101-104.
139. Edmonds ME, Roberts VC, Watkins PJ. Blood flow in the diabetic neuropathic foot. Diabetologia 1982. 22(1):9-15.
140. Edmonds ME, Morrison N, Laws JW, Watkins PJ. Medial arterial calcification and diabetic neuropathy. Br Med J (Clin Res Ed) 1982. 284(6320):928-930.
141. Corbin DO, Young RJ, Morrison DC, Hoskins P, McDicken WN, Housley E, Clarke BF. Blood flow in the foot, polyneuropathy and foot ulceration in diabetes mellitus. Diabetologia 1987. 30(7):468-473.
142. Young MJ, Adams JE, Anderson GF, Boulton AJ, Cavanagh PR. Medial arterial calcification in the feet of diabetic patients and matched non-diabetic control subjects. Diabetologia 1993. 36(7):615-621.
143. Charles M, Ejskjaer N, Witte DR, Borch-Johnsen K, Lauritzen T, Sandbaek A. Prevalence of neuropathy and peripheral arterial disease and the impact of treatment in people with screen-detected type 2 diabetes: the ADDITION-Denmark study. Diabetes Care 2011. 34(10):2244-2249.
144. Ybarra-Munoz J, Jurado-Campos J, Garcia-Gil M, Zabaleta-Del-Olmo E, Mir-Coll T, Zabalegui A, Vidal J, Romeo JH. Cardiovascular disease predicts diabetic peripheral polyneuropathy in subjects with type 2 diabetes: A 10-year prospective study. Eur J Cardiovasc Nurs 2014. In press.
145. Low SK, Sum CF, Yeoh LY, Tavintharan S, Ng XW, Lee SB, Tang WE, Lim SC. Prevalence of chronic kidney disease in adults with type 2 diabetes mellitus. Ann Acad Med Singapore 2015. 45(5):164-171.
146. Prasannakumar M, Rajput R, Seshadri K, Talwalkar P, Agarwal P, Gokulnath G, Kotak B, Raza A, Vasnawala H, Teli C, et al. An observational, cross-sectional study to assess the prevalence of chronic kidney disease in type 2 diabetes patients in India (START-India). Indian J Endocrinol Metab 2015. 19(4):520-523.
147. Papanas N, Liakopoulos V, Maltezos E, Stefanidis I. The diabetic foot in end stage renal disease. Ren Fail 2007. 29(5):519-528.
148. Agrawal RP, Ola V, Bishnoi P, Gothwal S, Sirohi P, Agrawal R. Prevalence of micro and macrovascular complications and their risk factors in type-2 diabetes mellitus. J Assoc Physicians India 2014. 62(6):504-508.
149. Bitirgen G, Ozkagnici A, Malik RA, Kerimoglu H. Corneal nerve fibre damage precedes diabetic retinopathy in patients with type 2 diabetes mellitus. Diabet Med 2014. 31:431-438.
150. Nitoda E, Kallinikos P, Pallikaris A, Moschandrea J, Amoiridis G, Ganotakis ES, Tsilimbaris M. Correlation of diabetic retinopathy and corneal neuropathy using confocal microscopy. Curr Eye Res 2012. 37:898-906.
151. Tahrani AA, Ali A, Raymond NT, Begum S, Dubb K, Mughal S, Jose B, Piya MK, Barnett AH, Stevens MJ. Obstructive sleep apnea and diabetic neuropathy: a novel association in patients with type 2 diabetes. Am J Respir Crit Care Med 2012. 186:434-441.
152. Fujihara K, Kodama S, Horikawa C, Yoshizawa S, Sugawara A, Hirasawa R, Shimano H, Yachi Y, Suzuki A, Hanyu O, et al. The relationship between diabetic neuropathy and sleep apnea syndrome: a meta-analysis. Sleep Disord 2013. 2013:150371.
153. Vas PR, Ahluwalia R, Manas AB, Manu CA, Kavarthapu V, Edmonds ME. Undiagnosed severe sleep apnoea and diabetic foot ulceration - a case series based hypothesis: a hitherto under emphasized factor in failure to heal. Diabet Med 2015. In press.
154. Papanas N, Steiropoulos P. Obstructive sleep apnoea and diabetic foot: new responsibilities? Angiology 2015. In press.
155. Pop-Busui R, Lu J, Brooks MM, Albert S, Althouse AD, Escobedo J, Green J, Palumbo P, Perkins BA, Whitehouse F, et al. Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care 2013. 36:3208-3215.
156. Calles-Escandon J, Lovato LC, Simons-Morton DG, Kendall DM, Pop-Busui R, Cohen RM, Bonds DE, Fonseca VA, Ismail-Beigi F, Banerji MA, et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010. 33:721-727.
157. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008. 358:580-591.
158. Sandbæk A, Griffin SJ, Sharp SJ, Simmons RK, Borch-Johnsen K, Rutten GE, van den Donk M, Wareham NJ, Lauritzen T, Davies MJ et al. Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with screen-detected diabetes: a randomized controlled trial: the ADDITION-Europe Study. Diabetes Care 2014. 37:2015-2023.
159. Charles M, Fleischer J, Witte DR, Ejskjaer N, Borch-Johnsen K, Lauritzen T, Sandbaek A. Impact of early detection and treatment of diabetes on the 6-year prevalence of cardiac autonomic neuropathy in people with screen-detected diabetes: ADDITION-Denmark, a cluster-randomised study. Diabetologia 2013. 56:101-108.